Regulator And Pharmaceutical Composition Encompassing The Regulator

Nan-Haw Chow (Inventor), Hsiao-Sheng Liu (Inventor), Wen-Tsan Chang (Inventor)

Research output: Patent

Abstract

The present disclosure is directed to a regulator, a pharmaceutical composition encompassing the regulator and the application thereof The regulator modulates the expression integrins and/or EMP2, and is employed for treating integrins-associated and/or EMP2-associated diseases
Original languageEnglish
Patent numberZL 2013 1 0177660.2
Publication statusPublished - 1800

Fingerprint

Integrins
Disclosure
Pharmaceutical Preparations

Cite this

@misc{93f23c3432974717a7e314e45b10079b,
title = "Regulator And Pharmaceutical Composition Encompassing The Regulator",
abstract = "The present disclosure is directed to a regulator, a pharmaceutical composition encompassing the regulator and the application thereof The regulator modulates the expression integrins and/or EMP2, and is employed for treating integrins-associated and/or EMP2-associated diseases",
author = "Nan-Haw Chow and Hsiao-Sheng Liu and Wen-Tsan Chang",
year = "1800",
language = "English",
type = "Patent",
note = "ZL 2013 1 0177660.2",

}

Regulator And Pharmaceutical Composition Encompassing The Regulator. / Chow, Nan-Haw (Inventor); Liu, Hsiao-Sheng (Inventor); Chang, Wen-Tsan (Inventor).

Patent No.: ZL 2013 1 0177660.2.

Research output: Patent

TY - PAT

T1 - Regulator And Pharmaceutical Composition Encompassing The Regulator

AU - Chow, Nan-Haw

AU - Liu, Hsiao-Sheng

AU - Chang, Wen-Tsan

PY - 1800

Y1 - 1800

N2 - The present disclosure is directed to a regulator, a pharmaceutical composition encompassing the regulator and the application thereof The regulator modulates the expression integrins and/or EMP2, and is employed for treating integrins-associated and/or EMP2-associated diseases

AB - The present disclosure is directed to a regulator, a pharmaceutical composition encompassing the regulator and the application thereof The regulator modulates the expression integrins and/or EMP2, and is employed for treating integrins-associated and/or EMP2-associated diseases

M3 - Patent

M1 - ZL 2013 1 0177660.2

ER -